Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham R Foster

Showing results (181-190 of 191) with videos related to

Pageof 20
Sort By:
Annals of Hepatology|April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trialsDonald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
BMC Medical Informatics and Decision Making|October 13, 2021
An informatics consult approach for generating clinical evidence for treatment decisionsAlvina G Lai, Wai Hoong Chang, Constantinos A Parisinos, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 2007
Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseasesAmy D Brideau-Andersen, Xiaojian Huang, Siu-Chi Chang Sun, et al.
The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trialsEdward J Gane, Stephen Pianko, Stuart K Roberts, et al.
Lancet (London, England)|November 27, 2018
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UKRoger Williams, Graeme Alexander, Richard Aspinall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 17, 2025
Association Between Sustained Virological Response and Adverse Liver-related Events in Patients With Decompensated Hepatitis C Virus CirrhosisLisa M van Velsen, Lisette A P Krassenburg, Grishma Hirode, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Pageof 20

Showing results (181-190 of 191) with videos related to

Sort By:
Pageof 20
Annals of Hepatology|April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trialsDonald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
BMC Medical Informatics and Decision Making|October 13, 2021
An informatics consult approach for generating clinical evidence for treatment decisionsAlvina G Lai, Wai Hoong Chang, Constantinos A Parisinos, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 2007
Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseasesAmy D Brideau-Andersen, Xiaojian Huang, Siu-Chi Chang Sun, et al.
The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trialsEdward J Gane, Stephen Pianko, Stuart K Roberts, et al.
Lancet (London, England)|November 27, 2018
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UKRoger Williams, Graeme Alexander, Richard Aspinall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 17, 2025
Association Between Sustained Virological Response and Adverse Liver-related Events in Patients With Decompensated Hepatitis C Virus CirrhosisLisa M van Velsen, Lisette A P Krassenburg, Grishma Hirode, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Pageof 20